


PATENT AND TRADEMARK OFFICE
FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17641 (BOT)		SERIAL NO.: 10/754,364
APPLICANT: MITHCEL F. BRIN		TITLE: METHODS FOR TREATING VASCULAR DISORDERS
FILING DATE: January 8, 2004		GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
leb	AA	09/371,354		Donovan, Stephen			8/10/1999
leb	AB	10/114,740		Brooks, Greg			4/1/2002
leb	AC	10/194,805		Donovan, Stephen			7/11/2002
leb	AD	5,437,291	8/1/1995	Pasricha et al.			
leb	AE	5,670,484	9/23/1997	Binder, William			
leb	AF	5,714,468	2/3/1998	Binder, William			
leb	AG	5,766,605	6/16/1998	Sanders et al.			
leb	AH	5,989,545	11/23/1999	Foster et al.			
leb	AI	6,063,768	5/16/2000	First, Eric			
leb	AJ	6,139,845	10/31/2000	Donovan, Stephen			
leb	AK	6,265,379	7/24/2001	Donovan, Stephen			
leb	AL	6,299,893	10/9/2001	Schwartz et al.			
leb	AM	6,306,423	10/23/2001	Donovan et al.			
leb	AN	6,312,708	11/6/2001	Donovan, Stephen			
leb	AO	6,358,926	3/19/2002	Donovan, Stephen			
leb	AP	6,423,319	7/23/2002	Brooks et al.			
leb	AQ	6,458,365	10/1/2002	Aoki et al.			
leb	AR	6,464,986	10/15/2002	Aoki et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
leb	BA	WO 01/10458	2/15/01	PCT			Yes
leb	BB	WO 03/084567	10/16/03	PCT			Yes

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

leb	CA	Bigalke H., et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> , Brain Research 360;318-324:1985
-----	----	--

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PATENT AND TRADEMARK OFFICE
FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17641 (BOT)		SERIAL NO.: 10/754,364
APPLICANT: MITHCEL F. BRIN		TITLE: METHODS FOR TREATING VASCULAR DISORDERS
FILING DATE: January 8, 2004		GROUP:


leb	CB	Bigalke H., et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord</i> , Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981
leb	CC	Binz T. et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> , J Biological Chemistry 265(16);9153-9158:1990
leb	CD	Bushara K., <i>Botulinum toxin and rhinorrhea</i> , Otolaryngol Head Neck Surg 1996;114(3):507
leb	CE	Duggan et al., <i>A Survey of Botulinum neurotoxin substrate expression in cells; Mov Disord</i> , 10(3):376:1995
leb	CF	Gonelle-Gispert et al., <i>Snap-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion; Biochem J</i> 1;339 (pt 1):159-65:1999
leb	CG	Habermann E., et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain</i> , J Neurochem 51(2);522-527:1988
leb	CH	Habermann E., <i>Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate</i> , Experientia 44;224-226:1988
leb	CI	<i>Harrison's Principles of Internal Medicine</i> (1998), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill
leb	CJ	Jankovic J. et al., <i>Therapy With Botulinum Toxin</i> , Marcel Dekker, Inc., (1994), page 5, 150
leb	CK	Moro E., et al, <i>Suppression of syncopes after botulinum toxin treatment</i> , Mov Disord 2002;17(Suppl 5):S242 ABS P780
leb	CL	Moyer E et al., <i>Botulinum Toxin Type B: Experimental and Clinical Experience</i> , being chapter 6, pages 71-85 of "Therapy With Botulinum Toxin", edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
leb	CM	Naumann et al., <i>Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions; European J. Neurology</i> 6 (Supp 4): S111-S1150:1999
leb	CN	Pearce, L.B., <i>Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine</i> , Toxicon 35(9);1373-1412 at 1393
leb	CO	Ragona et al., <i>Management of Parotid Sialoceles with Botulinum Toxin; The Laryngoscope</i> 109:1344-1346:1999

EXAMINER W. F. [Signature]DATE CONSIDERED 1/11/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PATENT AND TRADEMARK OFFICE
FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17641 (BOT)		SERIAL NO.: 10/754,364
APPLICANT: MITHCEL F. BRIN		TITLE: METHODS FOR TREATING VASCULAR DISORDERS
FILING DATE: January 8, 2004		GROUP:

leb	CP	Sanchez-Prieto, J., et al., <i>Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes</i> , Eur J. Biochem 165;675-681:1897
leb	CQ	Sterodimas, A., et al., <i>Successful use of botulinum toxin-A for the treatment of neck and anterior chest wall flushing</i> , Clinical and Experimental Dermatology, 2003 Blackwell Publishing Ltd., Vol. 28, Pg. 592-594
leb	CR	Schantz, E.J., et al, <i>Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine</i> , Microbiol Rev. 56;80-99:1992
leb	CS	Singh, <i>Critical Aspects of Bacterial Protein Toxins</i> , pages 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1976)
leb	CT	Sloop et al., <i>Reconstituted Botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use</i> , Neurology, 48:249-53:1997.
leb	CU	Tugnoli V., et al., <i>The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A</i> , Clin Auton Res 2002;12(3):174-178


EXAMINER



DATE CONSIDERED

1/11/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17641 (BOT)	SERIAL NO.: 10/754,364
APPLICANT: MITCHELL F. BRIN	TITLE: METHODS FOR TREATING VASCULAR DISORDERS
FILING DATE: January 8, 2004	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

lebo	CA	Kellogg, Jr., Dean L., et al., <i>Cutaneous Active Vasodilation in Humans is Mediated by Cholinergic Nerve Cotransmission</i> , Vol. 77(6), Dec. 1995, American Heart Association, Inc., Lippincott Williams & Wilkins, pp. 1222-1228.
	CB	
	CC	
	CD	
	CE	

EXAMINER

W. B. Brin

DATE CONSIDERED

1/11/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.